Business Overview: Replimune Group, Inc. (NASDAQ: REPL)

---

Executive Summary

Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies built on its proprietary RPx platform, an engineered herpes simplex virus 1 (HSV-1) backbone designed to directly kill tumor cells while triggering a systemic anti-tumor immune response. Headquartered with in-house manufacturing in Framingham, Massachusetts, the company's lead candidate RP1 (vusolimogene oderparepvec), combined with the anti-PD-1 therapy nivolumab, has been developed for advanced melanoma patients who have failed prior anti-PD-1 treatment.

The company matters as a bellwether for the oncolytic virus therapy category, but it now faces a defining crisis: after the FDA issued an initial Complete Response Letter (CRL) in mid-2025 despite Breakthrough Therapy designation and priority review, Replimune resubmitted its application and subsequently received a second CRL later in 2025, triggering a stock collapse of roughly 64% and workforce reductions covering about 60% of staff. The company has stated it intends to continue operating with cash runway reported into 2027.

---

1. Core Business Model & How They Work

[ Engineer HSV-1 backbone with immune-stimulating payloads ] ➡️ [ Direct intratumoral injection ] ➡️ [ Tumor cell lysis + systemic immune activation ] ➡️ [ Combine with checkpoint inhibitors (e.g. nivolumab) ] ➡️ [ Seek regulatory approval & commercialization ]

Key mechanics:

1. Platform-based pipeline: The RPx platform underlies multiple product candidates (RP1, RP2), allowing the company to leverage shared manufacturing and mechanism-of-action data across programs rather than developing each therapy from scratch.
2. Combination-therapy strategy: RP1 is developed in combination with BMS-supplied nivolumab (provided at no cost under a collaboration), reducing some direct drug-supply cost but tying commercial success to combination efficacy.
3. In-house manufacturing: A ~63,000 sq ft Framingham facility gives Replimune direct control over its complex viral manufacturing process rather than relying solely on contract manufacturers.
4. Regulatory-dependent value creation: As a clinical-stage biotech with no approved products, essentially all near-term value hinges on FDA approval outcomes rather than product sales.

---

2. Product Portfolio / Pipeline

---

3. Competitive Landscape

• Large pharmaceutical companies: Bristol Myers Squibb, Merck, and others with approved checkpoint inhibitors and far greater financial and commercial resources compete for the same advanced-melanoma treatment landscape.
• Other oncolytic virus developers: A small but growing field of companies pursuing engineered virus-based cancer therapies, competing for both clinical validation and capital.
• Cell therapy and cancer vaccine companies: Broader immuno-oncology competitors targeting similar post-checkpoint-inhibitor-failure patient populations.
• Replimune's own filings acknowledge facing competitors with substantially greater financial and development resources — a disadvantage now compounded by its regulatory setbacks and reduced headcount.

---

4. Strategic Strengths & Risks

Strengths

• Differentiated clinical data: In the IGNYTE study (140 anti-PD-1-failed melanoma patients), RP1 + nivolumab achieved a 33.6% overall response rate with 85% of responses lasting more than 12 months — clinically meaningful efficacy in a difficult-to-treat population.
• Platform optionality: RP2 and earlier-stage programs provide a path forward even if RP1's regulatory path for melanoma does not succeed.
• In-house manufacturing control: Reduces dependence on third-party contract manufacturers for a complex viral product.
• Intellectual property base: Six U.S. patents granted and six core PCT applications in national phase support platform protection.

Risks — materially elevated following 2025 events

• Two consecutive FDA Complete Response Letters for RP1: A highly unusual regulatory outcome for a Breakthrough Therapy-designated, priority-reviewed program, casting serious doubt on the asset's near-term approvability.
• Severe workforce reduction: Layoffs covering approximately 60% of staff following the second CRL signal a fundamental restructuring of the company's scale and ambitions.
• Binary regulatory/strategic outlook: The company's future now depends heavily on either resolving the FDA's concerns for RP1, pivoting resources fully to RP2, or pursuing strategic alternatives — with cash runway reported into 2027 providing a finite window.
• No approved products or product revenue: As with all clinical-stage biotechs, the company remains entirely dependent on capital markets and partnerships to fund operations.
• Competitive resource disadvantage: Competing against far larger, better-capitalized pharmaceutical companies in oncology.

---

5. Financial Overview

---

Summary Conclusion

Replimune built one of the more clinically credible oncolytic virus platforms in immuno-oncology, with durable response data for RP1 in a hard-to-treat melanoma population, but 2025 brought a severe reversal: two consecutive FDA Complete Response Letters for its lead program, a roughly 64% stock price collapse, and workforce reductions covering 60% of staff. The company says it will continue operating with cash runway into 2027, giving it a window to either resolve the FDA's concerns for RP1, redirect resources toward RP2 in uveal melanoma, or pursue strategic alternatives. The single biggest forward risk is now existential rather than merely competitive: whether Replimune can find any viable regulatory or strategic path forward for its platform before its cash runway expires, given that a technology platform with genuine clinical promise has, so far, twice failed to clear the FDA's approval bar.